Details of the Drug Pharmacogenomic Perturbation Atlas

PF-04457845 Drug Info

PF-04457845; 1020315-31-4; UNII-H4C81M8YYW; H4C81M8YYW; CHEMBL1651534; PF 04457845; PF04457845; C23H20F3N5O2; N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; N-Pyridazin-3-yl-4-((3-(5-(trifluoromethyl)pyridin-2-yl)oxyphenyl)methylidene)piperidine-1-carboxamide; 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-;1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-

Cross-matching ID

PubChem CID

24771824

ChEBI ID

CHEMBL1651534

CAS Number

CAS 1020315-31-4

TTD Drug ID

D0JT5I

General Information of Drug (ID: DMPRYU1)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Endocytosis	-1.67	4.84e-2	198/252 (78.57%)	GRK4;CHMP1A;GIT1;...
Staphylococcus aureus infection	-1.71	3.17e-2	72/95 (75.79%)	DEFA6;KRT14;C1S;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.72	2.65e-2	62/70 (88.57%)	MAPK11;ATP6V1B1;RAC1;...
Measles	-1.74	2.26e-2	133/139 (95.68%)	MAPK8;MAP3K7;IFNA2;...
Bladder cancer	-1.77	1.34e-2	40/41 (97.56%)	CDH1;MMP1;MMP9;...
Osteoclast differentiation	-1.77	1.48e-2	117/127 (92.13%)	MAPK8;MAP3K7;SYK;...
Phagosome	-1.80	9.58e-3	118/152 (77.63%)	CLEC7A;ATP6V1H;STX7;...
Oxidative phosphorylation	-1.81	1.08e-2	93/133 (69.92%)	ATP6V1H;ATP5MG;TCIRG1;...
Pathogenic Escherichia coli infection	-1.81	1.23e-2	152/197 (77.16%)	IL6;TLR5;RAC1;...
Steroid biosynthesis	-1.84	1.03e-2	19/20 (95%)	LIPA;EBP;SOAT1;...
Vibrio cholerae infection	-1.86	1.23e-2	44/50 (88%)	ATP6V1H;ERO1A;TCIRG1;...
Mitophagy	-1.87	1.54e-2	56/68 (82.35%)	MRAS;ATG5;TBC1D17;...
Hepatitis C	-1.94	2.05e-2	139/157 (88.54%)	NFKB1;TYK2;PIAS1;...
Lysosome	-1.94	1.85e-2	115/128 (89.84%)	IDUA;HYAL2;ATP6V0A2;...
IL-17 signaling pathway	-2.05	1.23e-2	84/94 (89.36%)	CCL7;JUND;HSP90AA1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 10uM	24H